D Medical Industries Ltd. (Nasdaq: DMED); TASE:DMDC) reports that its subsidiary Spring-Set Health Solutions Ltd. has successfully completed a usability and safety study of its of its Spring Universal Infusion Set for the delivery of insulin and other medications from an insulin pump.
The study included 48 patients at one medical center in New York. The study tested the interfaces between users, the system, and the use environments, with the endpoints being user success in performing each task. D Medical concluded, "Most users had high scores for satisfaction and the product was ranked safe for use by the intended population."
D Medical COO Hezkiah Tsoory said, "We conducted this study in preparation for, and in anticipation of, US Food and Drug Administration (FDA) 510(k) clearance for our Spring Universal Infusion Sets. That major accomplishment was achieved earlier this week. Now, as we make final preparations for a US roll-out, we are confident that the clear advantages of this product will win the hearts and minds of the American pump users."
D Medical's share price closed at $4.79 on Nasdaq yesterday, after rising 60% on Monday, giving a market cap of $37 million. The share price fell 5.6% by mid-afternoon on the TASE today to NIS 16.81.
Published by Globes [online], Israel business news - www.globes-online.com - on May 4, 2011
© Copyright of Globes Publisher Itonut (1983) Ltd. 2011